Regeneron (REGN +5.8%
) gains after blowing away Q3 estimates
earlier this morning. Total revenues soared over 300% Y/Y on strong demand for Eylea, REGN
's injection for the treatment of neovascular age-related macular degeneration. Sales of the drug were up 26% from 2Q. The company boost its sales estimates again for the year, and notes that Eylea should further fuel growth in 2013 following recent FDA approval for its expanded use.